HomeCompareREGMF vs STAG

REGMF vs STAG: Dividend Comparison 2026

REGMF yields 18.27% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REGMF wins by $47.3K in total portfolio value
10 years
REGMF
REGMF
● Live price
18.27%
Share price
$10.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.6K
Annual income
$5,575.28
Full REGMF calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — REGMF vs STAG

📍 REGMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREGMFSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REGMF + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REGMF pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REGMF
Annual income on $10K today (after 15% tax)
$1,552.64/yr
After 10yr DRIP, annual income (after tax)
$4,738.99/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, REGMF beats the other by $4,346.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REGMF + STAG for your $10,000?

REGMF: 50%STAG: 50%
100% STAG50/50100% REGMF
Portfolio after 10yr
$42.0K
Annual income
$3,018.75/yr
Blended yield
7.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

REGMF
No analyst data
Altman Z
6.7
Piotroski
7/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REGMF buys
0
STAG buys
0
No recent congressional trades found for REGMF or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREGMFSTAG
Forward yield18.27%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$65.6K$18.3K
Annual income after 10y$5,575.28$462.22
Total dividends collected$35.6K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: REGMF vs STAG ($10,000, DRIP)

YearREGMF PortfolioREGMF Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$12,527$1,826.63$10,665$345.09+$1.9KREGMF
2$15,542$2,138.47$11,364$357.70+$4.2KREGMF
3$19,110$2,479.65$12,098$370.43+$7.0KREGMF
4$23,297$2,849.38$12,869$383.28+$10.4KREGMF
5$28,174$3,246.45$13,677$396.23+$14.5KREGMF
6$33,815$3,669.26$14,524$409.27+$19.3KREGMF
7$40,298$4,115.87$15,411$422.41+$24.9KREGMF
8$47,703$4,584.06$16,339$435.61+$31.4KREGMF
9$56,114$5,071.40$17,311$448.89+$38.8KREGMF
10$65,617$5,575.28$18,327$462.22+$47.3KREGMF

REGMF vs STAG: Complete Analysis 2026

REGMFStock

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.

Full REGMF Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this REGMF vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REGMF vs SCHDREGMF vs JEPIREGMF vs OREGMF vs KOREGMF vs MAINREGMF vs PLDREGMF vs EQRREGMF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.